Anne Floquet

ORCID: 0000-0002-1078-8554 · 2 papers in corpus

2024

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.

Nature communications ·doi:10.1038/s41467-024-45974-w

Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic activity. This open-label phase 2 study (NCT04015739) aimed to …

article 2021

Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study

Gynecologic Oncology ·doi:10.1016/j.ygyno.2021.10.001

ObjectiveWe have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gyne…